Capstone Investment Advisors
ALXN

Capstone Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Capstone Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,400
Closed -$4.67M – 2119
2021
Q2 		$4.67M Sell
25,400
-100
-0.4% -$17.2K 0.01% 741
2021
Q1 		$3.9M Sell
25,500
-7,800
-23% -$1.21M 0.01% 716
2020
Q4 		$5.2M Buy
33,300
+5,300
+19% +$681K 0.02% 578
2020
Q3 		$3.2M Buy
28,000
+8,600
+44% +$928K 0.02% 653
2020
Q2 		$2.18M Buy
19,400
+8,600
+80% +$913K 0.01% 692
2020
Q1 		$970K Sell
10,800
-29,100
-73% -$2.86M 0.02% 721
2019
Q4 		$4.32M Buy
39,900
+5,900
+17% +$631K 0.02% 610
2019
Q3 		$3.33M Buy
34,000
+13,300
+64% +$1.5M 0.02% 578
2019
Q2 		$2.71M Buy
20,700
+7,900
+62% +$1.02M 0.02% 656
2019
Q1 		$1.73M Buy
12,800
+6,500
+103% +$808K 0.02% 657
2018
Q4 		$613K Buy
6,300
+4,200
+200% +$496K 0.01% 770
2018
Q3 		$292K Buy
+2,100
New +$263K ﹤0.01% 922

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Capstone Investment Advisors's ALXN Position: Q3 2021 in Review

Capstone Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 868,549 shares — an estimated $160M sold.

Capstone Investment Advisors first reported a position in ALXN in Q1 2016 and held it in 12 quarters. The position peaked at $180M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Capstone Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 868,549 Alexion Pharmaceuticals shares in Q3 2021, an estimated $160M.
  • Capstone Investment Advisors first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 12 quarters.
  • Capstone Investment Advisors's Alexion Pharmaceuticals position peaked at $180M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Capstone Investment Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.